Multipoint pacing of the left ventricle to achieve better resynchronisation and clinical response

2016 ◽  
pp. 84-84 ◽  
Author(s):  
Marcin Michalak ◽  
Andrzej Cacko ◽  
Przemysław Stolarz ◽  
Marcin Grabowski
Heart Rhythm ◽  
2021 ◽  
Vol 18 (8) ◽  
pp. S174-S175
Author(s):  
Peter Henry Waddingham ◽  
Michele Orini ◽  
Jan Mangual ◽  
Amal G. Muthumala ◽  
Simon Sporton ◽  
...  

EP Europace ◽  
2021 ◽  
Vol 23 (Supplement_3) ◽  
Author(s):  
M Brandao ◽  
J Goncalves Almeida ◽  
P Fonseca ◽  
F Rosas ◽  
E Santos ◽  
...  

Abstract Funding Acknowledgements Type of funding sources: None. BACKGROUND  Upgrade to  resynchronization therapy (CRT) is common practice in Europe. However, patient selection remains a challenge. Data regarding predictors of response to upgrade is currently lacking. AIM To identify predictors of clinical response after upgrade to CRT. METHODS Single-center retrospective study of consecutive patients submitted to upgrade to CRT (2007-2018). Patients underwent clinical and echocardiographic (echo) evaluation at baseline, 6-months and 1-year. Major adverse cardiac events (MACE) included hospitalization for heart failure (HF) or all-cause mortality. Clinical response was defined as New York Heart Association (NYHA) class improvement without MACE in the 1st year of follow-up (FU). Left ventricle end-systolic volume reduction of >15% designated echo response. Multivariate logistic regression was performed to identify predictors of clinical response to CRT. RESULTS Fifty-six patients submitted to upgrade to CRT (80.4% male, mean age 70.0 ± 9.6 years) were included; 43 patients (78.2%) previously had a pacemaker and 12 (21.8%) had a defibrillator device.  Most patients had non-ischemic HF (67.9%), with a mean baseline left ventricle (LV) ejection fraction of 27.9 ± 6.4%. Indications for upgrade were mainly pacemaker dependency or pacing-induced LV dysfunction (76.6%) and de novo left bundle branch block (23.4%). Thirty-one (59.3%) patients were clinical responders. MACE occurred in 37.5% of patients; 28.6% were hospitalized for HF and 13% died during the 1st year of FU. Clinical responders had a lower rate of atrial fibrillation (AF) (46.9% vs. 53.1%, p=.025) and a higher rate of pacemaker rythm prior to upgrade (80.6% vs 47.6%, p=.013). Among responders, the previous device was more frequently a pacemaker (87.5% vs 61.9%, p=.029), and the new device a CRT-P (81.2% vs 54.5%, p=.035). HF etiology did not differ between responders and non-responders. Multivariate analysis identified absence of AF (odds ratio [OR] 4.4, 95% confidence interval [CI] 1.1-17.6, p=.037), CRT-P (OR 5.7, 95% CI 1.3-25.8, p=.022) and quadripolar lead implant (OR 3.8, 95% CI 1.3-25.8, p=.024) as predictors of clinical response in upgraded patients. CONCLUSIONS In this cohort, absence of AF, implantation of CRT-P and use of a quadripolar lead predicted clinical response to upgrade to CRT. Larger studies are warranted to tailor selection of patients for upgrade procedures.


2010 ◽  
Vol 20 (3) ◽  
pp. 76-83 ◽  
Author(s):  
Joseph Donaher ◽  
Tom Gurrister ◽  
Irving Wollman ◽  
Tim Mackesey ◽  
Michelle L. Burnett

Parents of children who stutter and adults who stutter frequently ask speech-language pathologists to predict whether or not therapy will work. Even though research has explored risk-factors related to persistent stuttering, there remains no way to determine how an individual will react to a specific therapy program. This paper presents various clinicians’answers to the question, “What do you tell parents or adults who stutter when they ask about cure rates, outcomes, and therapy efficacy?”


2001 ◽  
Vol 120 (5) ◽  
pp. A253-A253
Author(s):  
V YANG ◽  
R CASERO ◽  
D GEIMAN ◽  
W HUBBARD ◽  
L HYLIND ◽  
...  
Keyword(s):  

1999 ◽  
Vol 1 ◽  
pp. S101-S101
Author(s):  
O FOKINA ◽  
N TVERDOKHLEBOV ◽  
V SANDRIKOV ◽  
L KOUZNETZOVA

Sign in / Sign up

Export Citation Format

Share Document